FDA Review Sought for New Point-of-Care Vaginitis Test

Diagnostics company bioMérieux has filed for FDA clearance of a rapid PCR test designed to identify the cause of vaginitis — including bacterial vaginosis — in about 20 minutes, right in a clinician's office.

In this article:

• What was submitted
• Why current vaginitis testing falls short
• How the new panel works
• Why this matters for chronic UTI/BV patients

What Was Submitted

bioMérieux filed a dual 510(k) and CLIA waiver application with the FDA for its Biofire Spotfire vaginitis panel, an automated, multiplex PCR test built to detect common causes of vaginitis at the point of care. The filing marks the company's first move into the women's and sexual health diagnostics space.

Why Current Testing Falls Short

Vaginitis — an umbrella term covering bacterial vaginosis, yeast infections, and trichomoniasis — is common but frequently gets missed or only partly identified. Traditional, non-molecular testing methods often lack the sensitivity to fully characterize the condition, according to bioMérieux, and the company's own data suggests only about half of women diagnosed this way end up on appropriate treatment.

That gap matters clinically. As bioMérieux's chief medical officer noted, vaginitis symptoms aren't just disruptive — the underlying condition is also linked to pelvic inflammatory disease, cervical cancer, adverse birth outcomes, and secondary infections.

How the New Panel Works

The Spotfire vaginitis panel reports eight results from a single swab, covering bacterial vaginosis along with yeast and parasite pathogens, with the full 20-minute turnaround timed to fit inside a standard patient visit. It runs on the existing Biofire Spotfire instrument, a modular system already used for respiratory and sore throat testing in a range of care settings.

A company clinical operations executive framed the submission as an attempt to close a persistent gap between the need for accurate, comprehensive vaginitis testing and the reality of delayed or incomplete results in everyday practice. Beyond the US filing, bioMérieux also plans to seek CE marking for the panel in the European Union.

Why This Matters

For patients cycling through repeat vaginitis or BV episodes, misdiagnosis is often the root problem — not treatment failure. A same-visit molecular test that distinguishes BV from yeast infection or trichomoniasis, rather than relying on symptom overlap or slower lab-based methods, could shorten the time to correct treatment and cut down on inappropriate antibiotic or antifungal use. It's also a signal that diagnostics makers see meaningful commercial demand in the BV/vaginitis space — worth watching as it moves through FDA review.

Treatment options using Biome and Beyond Bioclear Ozone Suppositories

Our BioClear ozone suppositories are formulated to deliver this therapy in a gentle, non-irritating format that can be used at home under appropriate guidance. They fill a critical gap for women who are seeking a natural, non-azole option, whether because of resistance concerns, pregnancy considerations, or a desire to avoid repeated rounds of pharmaceuticals. The goal is not just symptom relief but restoration of the vaginal environment.

Ozone is a naturally occurring molecule composed of three oxygen atoms. In a therapeutic context, it acts as a powerful yet selective oxidant. When delivered vaginally via a suppository, ozone disrupts the cell membranes of yeast and harmful bacteria without the mechanism that promotes resistance. Equally important, ozone oxygenates the local tissues, which supports immune function and encourages healthy tissue repair. This dual action, addressing both the pathogen and the terrain, is what sets ozone therapy apart.

Conclusion

This is a regulatory filing, not yet a market launch — FDA clearance timelines vary, and there's no confirmed date for availability. But it points to real momentum in improving vaginitis diagnostics, an area that directly affects chronic UTI and BV patients navigating repeat, hard-to-pin-down infections.

Sources

• Clinical Lab Products, "bioMérieux Seeks FDA Authorization for Point-of-Care Vaginitis Test" (June 26, 2026): clpmag.com